Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Celgene Corporation stock

Own Celgene Corporation stock in just a few minutes.


Fact checked

Celgene Corporation is a drug manufacturers-general business based in the US. Celgene Corporation shares (CELG) are listed on the NASDAQ and all prices are listed in US Dollars. Celgene Corporation employs 8,852 staff and has a trailing 12-month revenue of around USD$17 billion.

How to buy shares in Celgene Corporation

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Celgene Corporation. Find the stock by name or ticker symbol: CELG. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Celgene Corporation reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. Weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Celgene Corporation, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Celgene Corporation. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Celgene Corporation share price

Use our graph to track the performance of CELG stocks over time.

Celgene Corporation shares at a glance

Information last updated 2020-04-13.
52-week rangeUSD$0 - USD$0
50-day moving average USD$108.24
200-day moving average USD$104.3553
Wall St. target priceUSD$103.4
PE ratio 13.33
Dividend yield N/A (0%)
Earnings per share (TTM) USD$8.133

Buy Celgene Corporation shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee
Sofi Invest
Stocks, ETFs, Cryptocurrency
A free way to invest in stocks, ETFs and crypto.
Interactive Brokers
Stocks, Forex
$0 + $0.65/contract, $1 minimum
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Stocks, ETFs
Stocks, Options, ETFs, Cryptocurrency
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
$0 for US stocks
Stocks, Options, ETFs
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Celgene Corporation stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Is Celgene Corporation under- or over-valued?

Valuing Celgene Corporation stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Celgene Corporation's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Celgene Corporation's P/E ratio

Celgene Corporation's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 13x. In other words, Celgene Corporation shares trade at around 13x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.

Celgene Corporation's PEG ratio

Celgene Corporation's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.86. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Celgene Corporation's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

Celgene Corporation's EBITDA

Celgene Corporation's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$8.9 billion.

The EBITDA is a measure of a Celgene Corporation's overall financial performance and is widely used to measure a its profitability.

Celgene Corporation financials

Revenue TTM USD$17 billion
Operating margin TTM 48.75%
Gross profit TTM USD$14.1 billion
Return on assets TTM 13.69%
Return on equity TTM 69.39%
Profit margin 34.63%
Book value $16.99
Market capitalisation USD$77 billion

TTM: trailing 12 months

Shorting Celgene Corporation shares

There are currently 12.0 million Celgene Corporation shares held short by investors – that's known as Celgene Corporation's "short interest". This figure is 4.8% down from 12.6 million last month.

There are a few different ways that this level of interest in shorting Celgene Corporation shares can be evaluated.

Celgene Corporation's "short interest ratio" (SIR)

Celgene Corporation's "short interest ratio" (SIR) is the quantity of Celgene Corporation shares currently shorted divided by the average quantity of Celgene Corporation shares traded daily (recently around 3.5 million). Celgene Corporation's SIR currently stands at 3.45. In other words for every 100,000 Celgene Corporation shares traded daily on the market, roughly 3450 shares are currently held short.

However Celgene Corporation's short interest can also be evaluated against the total number of Celgene Corporation shares, or, against the total number of tradable Celgene Corporation shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Celgene Corporation's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Celgene Corporation shares in existence, roughly 20 shares are currently held short) or 0.0185% of the tradable shares (for every 100,000 tradable Celgene Corporation shares, roughly 19 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Celgene Corporation.

Find out more about how you can short Celgene Corporation stock.

Celgene Corporation's environmental, social and governance track record

Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Celgene Corporation.

When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.

Celgene Corporation's total ESG risk score

Total ESG risk: 23.71

Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Celgene Corporation's overall score of 23.71 (as at 01/01/2019) is excellent – landing it in it in the 3rd percentile of companies rated in the same sector.

ESG scores are increasingly used to estimate the level of risk a company like Celgene Corporation is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).

Celgene Corporation's environmental score

Environmental score: 1.02/100

Celgene Corporation's environmental score of 1.02 puts it squarely in the 2nd percentile of companies rated in the same sector. This could suggest that Celgene Corporation is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.

Celgene Corporation's social score

Social score: 14.4/100

Celgene Corporation's social score of 14.4 puts it squarely in the 2nd percentile of companies rated in the same sector. This could suggest that Celgene Corporation is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.

Celgene Corporation's governance score

Governance score: 5.29/100

Celgene Corporation's governance score puts it squarely in the 2nd percentile of companies rated in the same sector. That could suggest that Celgene Corporation is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.

Celgene Corporation's controversy score

Controversy score: 2/5

ESG scores also evaluate any incidences of controversy that a company has been involved in. Celgene Corporation scored a 2 out of 5 for controversy – the second-highest score possible, reflecting that Celgene Corporation has, for the most part, managed to keep its nose clean.

Environmental, social, and governance (ESG) summary

Celgene Corporation was last rated for ESG on: 2019-01-01.

Total ESG score 23.71
Total ESG percentile 2.75
Environmental score 1.02
Environmental score percentile 2
Social score 14.4
Social score percentile 2
Governance score 5.29
Governance score percentile 2
Level of controversy 2

Celgene Corporation share dividends

We're not expecting Celgene Corporation to pay a dividend over the next 12 months.

Have Celgene Corporation's shares ever split?

Celgene Corporation's shares were split on a 2:1 basis on 26 June 2014. So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your Celgene Corporation shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for Celgene Corporation shares which in turn could have impacted Celgene Corporation's share price.

Celgene Corporation share price volatility

Over the last 12 months, Celgene Corporation's shares have ranged in value from as little as $0 up to $0. A popular way to gauge a stock's volatility is its "beta".

CELG.US volatility(beta: 1.41)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Celgene Corporation's is 1.4131. This would suggest that Celgene Corporation's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Celgene Corporation overview

Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma (MM), myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis and psoriasis; and ABRAXANE to treat breast, non-small cell lung, pancreatic, and gastric cancers. The company's products also include IDHIFA for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (rrAML) with an isocitrate dehydrogenase-2 mutation; VIDAZA, a pyrimidine nucleoside analog for intermediate-2 and high-risk MDS, chronic myelomonocytic leukemia, and AML; THALOMID to treat patients with MM; and ISTODAX, an epigenetic modifier. Its preclinical and clinical-stage product candidates include small molecules, biologics, and cell therapies for immune-inflammatory diseases, myeloid diseases, epigenetics, protein homeostasis, and immuno-oncology. The company has agreements with BeiGene, Ltd; Acceleron Pharma, Inc.; Agios Pharmaceuticals, Inc.; bluebird bio, Inc.; Lycera Corp.; Juno Therapeutics, Inc.; EXSCIENTIA LTD.; and IMIDomics SL, as well as immuno-oncology collaboration with Sutro Biopharma. The company also has strategic collaboration with Skyhawk Therapeutics, Inc. to discover and develop novel small molecules that modulate RNA splicing. Celgene Corporation was founded in 1980 and is headquartered in Summit, New Jersey. As of November 20, 2019, Celgene Corporation operates as a subsidiary of Bristol-Myers Squibb Company.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site